Author:
Kohl Tobias,Grabbert Markus,Heidenreich Axel
Publisher
Springer Berlin Heidelberg
Reference35 articles.
1. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (Hrsg) (2010) SEER cancer statistics review, 1975–2007. National Cancer Institute, Bethesda. https://seer.cancer.gov/csr/1975_2007/
2. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192–1202
3. Bonn SE, Sjolander A, Lagerros YT, Wiklund F, Stattin P, Holmberg E, Gronberg H, Balter K (2015) Physical activity and survival among men diagnosed with prostate cancer. Cancer Epidemiol Biomark Prev 24:57–64
4. Bonn SE, Barnett MJ, Thornquist M, Goodman G, Neuhouser ML (2018) Body mass index and prostate cancer risk in the Carotene and Retinol Efficacy Trial. LID – Eur J Cancer Prev 28(3):212–219. https://doi.org/10.1097/CEJ.0000000000000438
5. Bratt O, Drevin L, Akre O, Garmo H, Stattin P (2016) Family history and probability of prostate cancer, differentiated by risk category: a nationwide population-based study. J Natl Cancer Inst 108(10). https://doi.org/10.1093/jnci/djw110